Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effects of B/F/TAF on CFR in HIV
NCT03656783Phase 3Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Sep 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Brigham and Women's Hospital. Primary endpoint: Change in Global Coronary Flow Reserve at 24 weeks. Started Sep 2018; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT03656783.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03656783.